The proposed US Most Favored Nation (MFN) policy has the potential to significantly influence global P&MA strategy development, but its impact will likely even go far beyond this, affecting diverse corporate functions such as e.g. R&D, BD&L, and commercial. While many questions remain, pharmaceutical and biotech companies are already evaluating how they can prepare for a range of possible outcomes.
In this webinar, Simon-Kucher experts will share their latest perspectives on the MFN policy, discuss what it could mean for global pricing and market access, and explore practical approaches to preparing commercial strategies and designing global P&MA strategies in an uncertain environment.
Participants will learn:
- The latest developments and our early perspectives on the potential impact of the US MFN policy on global P&MA and beyond
- How pharmaceutical and biotech companies need to prepare their P&MA strategies for the brave new MFN environment and how this will affect other corporate functions such as R&D, BD&L, and commercial
- Key considerations when designing and executing forward-looking P&MA research under changing MFN scenarios
This webinar is free of charge.
Event details:
Tuesday, July 28, 2026: 4:00 - 5:00 p.m. CEST | 10:00 - 11:00 a.m. EDT
